Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)

Amylyx Pharmaceuticals has reported Capital Expenditures over the past 5 years, most recently at $86000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $86000.0 for Q4 2025, up 330.0% from a year ago — trailing twelve months through Dec 2025 was $138000.0 (down 12.1% YoY), and the annual figure for FY2025 was $138000.0, down 12.1%.
  • Capital Expenditures for Q4 2025 was $86000.0 at Amylyx Pharmaceuticals, up from $24000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for AMLX hit a ceiling of $1.1 million in Q2 2022 and a floor of -$19000.0 in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $153000.0 (2021), compared with a mean of $232368.4.
  • Biggest five-year swings in Capital Expenditures: surged 2342.86% in 2022 and later plummeted 105.32% in 2024.
  • Amylyx Pharmaceuticals' Capital Expenditures stood at $186000.0 in 2021, then surged by 233.33% to $620000.0 in 2022, then crashed by 42.58% to $356000.0 in 2023, then crashed by 94.38% to $20000.0 in 2024, then surged by 330.0% to $86000.0 in 2025.
  • The last three reported values for Capital Expenditures were $86000.0 (Q4 2025), $24000.0 (Q3 2025), and $17000.0 (Q2 2025) per Business Quant data.